Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2005

Open Access 01-10-2005 | Research article

Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells

Authors: Rafat A Siddiqui, Mustapha Zerouga, Min Wu, Alicia Castillo, Kevin Harvey, Gary P Zaloga, William Stillwell

Published in: Breast Cancer Research | Issue 5/2005

Login to get access

Abstract

Introduction

Epidemiological evidence strongly links fish oil, which is rich in docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), with low incidences of several types of cancer. The inhibitory effects of omega-3 polyunsaturated fatty acids on cancer development and progression are supported by studies with cultured cells and animal models. Propofol (2,6-diisopropylphenol) is the most extensively used general anesthetic–sedative agent employed today and is nontoxic to humans at high levels (50 μg/ml). Clinically relevant concentrations of propofol (3 to 8 μg/ml; 20 to 50 μM) have also been reported to have anticancer activities. The present study describes the synthesis, purification, characterization and evaluation of two novel anticancer conjugates, propofol-docosahexaenoate (propofol-DHA) and propofol-eicosapentaenoate (propofol-EPA).

Methods

The conjugates linking an omega-3 fatty acid, either DHA or EPA, with propofol were synthesized and tested for their effects on migration, adhesion and apoptosis on MDA-MB-231 breast cancer cells.

Results

At low concentrations (25 μM), DHA, EPA or propofol alone or in combination had minimal effect on cell adhesion to vitronectin, cell migration against serum and the induction of apoptosis (only 5 to 15% of the cells became apoptotic). In contrast, the propofol-DHA or propofol-EPA conjugates significantly inhibited cell adhesion (15 to 30%) and migration (about 50%) and induced apoptosis (about 40%) in breast cancer cells.

Conclusion

These results suggest that the novel propofol-DHA and propofol-EPA conjugates reported here may be useful for the treatment of breast cancer.
Appendix
Available only for authorised users
Literature
1.
Bang HO, Dyerberg J: Plasma lipids and lipoproteins in Greenlandic west coast Eskimos. Acta Med Scand. 1972, 192: 85-94.CrossRefPubMed
2.
Vogel VG, McPherson RS: Dietary epidemiology of colon cancer. Hematol Oncol Clin North Am. 1989, 3: 35-63.PubMed
3.
Kaizer L, Boyd NF, Kriukov V, Tritchler D: Fish consumption and breast cancer risk: an ecological study. Nutr Cancer. 1989, 12: 61-68.CrossRefPubMed
4.
Schloss I, Kidd MS, Tichelaar HY, Young GO, O'Keefe SJ: Dietary factors associated with a low risk of colon cancer in coloured west coast fishermen. S Afr Med J. 1997, 87: 152-158.PubMed
5.
Berg JP, Glattre E, Haldorsen T, Hostmark AT, Bay IG, Johansen AF, Jellum E: Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway. Cancer Causes Control. 1994, 5: 433-439. 10.1007/BF01694757.CrossRefPubMed
6.
Terry P, Lichtenstein P, Feychting M, Ahlbom A, Wolk A: Fatty fish consumption and risk of prostate cancer. Lancet. 2001, 357: 1764-1766. 10.1016/S0140-6736(00)04889-3.CrossRefPubMed
7.
Noguchi M, Minami M, Yagasaki R, Kinoshita K, Earashi M, Kitagawa H, Taniya T, Miyazaki I: Chemoprevention of DMBA-induced mammary carcinogenesis in rats by low-dose EPA and DHA. Br J Cancer. 1997, 75: 348-353.CrossRefPubMedPubMedCentral
8.
Rose DP, Connolly JM, Coleman M: Effect of omega-3 fatty acids on the progression of metastases after the surgical excision of human breast cancer cell solid tumors growing in nude mice. Clin Cancer Res. 1996, 2: 1751-1756.PubMed
9.
Jenski LJ, Zerouga M, Stillwell W: Omega-3 fatty acid-containing liposomes in cancer therapy. Proc Soc Exp Biol Med. 1995, 210: 227-233.CrossRefPubMed
10.
Norrish AE, Skeaff CM, Arribas GL, Sharpe SJ, Jackson RT: Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer. 1999, 81: 1238-1242. 10.1038/sj.bjc.6690835.CrossRefPubMedPubMedCentral
11.
Calviello G, Palozza P, Maggiano N, Franceschelli P, Di Nicuolo F, Marcocci ME, Bartoli GM: Effects of eicosapentaenoic and docosahexaenoic acids dietary supplementation on cell proliferation and apoptosis in rat colonic mucosa. Lipids. 1999, S111-
12.
Calviello G, Palozza P, Maggiano N, Piccioni E, Franceschelli P, Frattucci A, Di Nicuolo F, Bartoli GM: Cell proliferation, differentiation, and apoptosis are modified by n-3 polyunsaturated fatty acids in normal colonic mucosa. Lipids. 1999, 34: 599-604.CrossRefPubMed
13.
Calviello G, Palozza P, Piccioni E, Maggiano N, Frattucci A, Franceschelli P, Bartoli GM: Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer. 1998, 75: 699-705. 10.1002/(SICI)1097-0215(19980302)75:5<699::AID-IJC7>3.0.CO;2-U.CrossRefPubMed
14.
Madhavi N, Das UN: Effect of n–6 and n–3 fatty acids on the survival of vincristine sensitive and resistant human cervical carcinoma cells in vitro. Cancer Lett. 1994, 84: 31-41. 10.1016/0304-3835(94)90355-7.CrossRefPubMed
15.
Rose DP, Connolly JM: Antiangiogenicity of docosahexaenoic acid and its role in the suppression of breast cancer cell growth in nude mice. Int J Oncol. 1999, 15: 1011-1015.PubMed
16.
Hatala MA, Rayburn J, Rose DP: Comparison of linoleic acid and eicosapentaenoic acid incorporation into human breast cancer cells. Lipids. 1994, 29: 831-837.CrossRefPubMed
17.
Rose DP, Connolly JM: Effects of fatty acids and inhibitors of eicosanoid synthesis on the growth of a human breast cancer cell line in culture. Cancer Res. 1990, 50: 7139-7144.PubMed
18.
Covington H: Use of propofol for sedation in the ICU. Crit Care Nurse. 1998, 18: 34-39.PubMed
19.
Miller RD: Local anesthetics: anesthesia. Local Anesthetics. Edited by: Miller RD. 2000, New York: Churchill Livingstone, 491-521. 5
20.
Coetzee JF, Glen JB, Wium CA, Boshoff L: Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets. Anesthesiology. 1995, 82: 1328-1345. 10.1097/00000542-199506000-00003.CrossRefPubMed
21.
Eriksson O, Pollesello P, Saris NE: Inhibition of lipid peroxidation in isolated rat liver mitochondria by the general anaesthetic propofol. Biochem Pharmacol. 1992, 44: 391-393. 10.1016/0006-2952(92)90026-F.CrossRefPubMed
22.
Murphy PG, Myers DS, Davies MJ, Webster NR, Jones JG: The antioxidant potential of propofol (2,6-diisopropylphenol). Br J Anaesth. 1992, 68: 613-618.CrossRefPubMed
23.
Tsuchiya M, Asada A, Maeda K, Ueda Y, Sato EF, Shindo M, Inoue M: Propofol versus midazolam regarding their antioxidant activities. Am J Respir Crit Care Med. 2001, 163: 26-31.CrossRefPubMed
24.
Aarts L, van der Hee R, Dekker I, de Jong J, Langemeijer H, Bast A: The widely used anesthetic agent propofol can replace alpha-tocopherol as an antioxidant. FEBS Lett. 1995, 357: 83-85. 10.1016/0014-5793(94)01337-Z.CrossRefPubMed
25.
Hemmings HC, Adamo AI: Effects of halothane and propofol on purified brain protein kinase C activation. Anesthesiology. 1994, 81: 147-155.CrossRefPubMed
26.
Kanaya N, Gable B, Murray PA, Damron DS: Propofol increases phosphorylation of troponin I and myosin light chain 2 via protein kinase C activation in cardiomyocytes. Anesthesiology. 2003, 98: 1363-1371. 10.1097/00000542-200306000-00010.CrossRefPubMed
27.
Horibe M, Kondo I, Damron DS, Murray PA: Propofol attenuates capacitative calcium entry in pulmonary artery smooth muscle cells. Anesthesiology. 2001, 95: 681-688. 10.1097/00000542-200109000-00022.CrossRefPubMed
28.
Kanaya N, Murray PA, Damron DS: Propofol increases myofilament Ca2+ sensitivity and intracellular pH via activation of Na+-H+ exchange in rat ventricular myocytes. Anesthesiology. 2001, 94: 1096-1104. 10.1097/00000542-200106000-00026.CrossRefPubMed
29.
Mammoto T, Mukai M, Mammoto A, Yamanaka Y, Hayashi Y, Mashimo T, Kishi Y, Nakamura H: Intravenous anesthetic, propofol inhibits invasion of cancer cells. Cancer Lett. 2002, 184: 165-170. 10.1016/S0304-3835(02)00210-0.CrossRefPubMed
30.
Tsuchiya M, Asada A, Arita K, Utsumi T, Yoshida T, Sato EF, Utsumi K, Inoue M: Induction and mechanism of apoptotic cell death by propofol in HL-60 cells. Acta Anaesthesiol Scand. 2002, 46: 1068-1074. 10.1034/j.1399-6576.2002.460903.x.CrossRefPubMed
31.
Eder K, Reichlmayr-Lais AM, Kirchgessner M: Studies on the methanolysis of small amounts of purified phospholipids for gas chromatographic analysis of fatty acid methyl esters. J Chromatogr. 1992, 607: 55-67. 10.1016/0021-9673(92)87054-C.CrossRefPubMed
32.
Siddiqui RA, English D: Phosphatidylinositol 3'-kinase-mediated calcium mobilization regulates chemotaxis in phosphatidic acid-stimulated human neutrophils. Biochim Biophys Acta. 2000, 1483: 161-173.CrossRefPubMed
33.
Ito A, Uehara T, Tokumitsu A, Okuma Y, Nomura Y: Possible involvement of cytochrome c release and sequential activation of caspases in ceramide-induced apoptosis in SK-N-MC cells. Biochim Biophys Acta. 1999, 1452: 263-274. 10.1016/S0167-4889(99)00131-7.CrossRefPubMed
34.
Takahashi M, Fukutake M, Isoi T, Fukuda K, Sato H, Yazawa K, Sugimura T, Wakabayashi K: Suppression of azoxymethane-induced rat colon carcinoma development by a fish oil component, docosahexaenoic acid (DHA). Carcinogenesis. 1997, 18: 1337-1342. 10.1093/carcin/18.7.1337.CrossRefPubMed
35.
Kafrawy O, Zerouga M, Stillwell W, Jenski LJ: Docosahexaenoic acid in phosphatidylcholine mediates cytotoxicity more effectively than other omega-3 and omega-6 fatty acids. Cancer Lett. 1998, 132: 23-29. 10.1016/S0304-3835(98)00163-3.CrossRefPubMed
36.
Bradley MO, Swindell CS, Anthony FH, Witman PA, Devanesan P, Webb NL, Baker SD, Wolff AC, Donehower RC: Tumor targeting by conjugation of DHA to paclitaxel. J Control Release. 2001, 74: 233-236. 10.1016/S0168-3659(01)00321-2.CrossRefPubMed
37.
Zerouga M, Stillwell W, Jenski LJ: Synthesis of a novel phosphatidylcholine conjugated to docosahexaenoic acid and methotrexate that inhibits cell proliferation. Anticancer Drugs. 2002, 13: 301-311. 10.1097/00001813-200203000-00012.CrossRefPubMed
38.
Connolly JM, Gilhooly EM, Rose DP: Effects of reduced dietary linoleic acid intake, alone or combined with an algal source of docosahexaenoic acid, on MDA-MB-231 breast cancer cell growth and apoptosis in nude mice. Nutr Cancer. 1999, 35: 44-49. 10.1207/S1532791444-49.CrossRefPubMed
39.
Bogenrieder T, Herlyn M: Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 2003, 22: 6524-6536. 10.1038/sj.onc.1206757.CrossRefPubMed
40.
41.
Williams EE, Jenski LJ, Stillwell W: Docosahexaenoic acid (DHA) alters the structure and composition of membranous vesicles exfoliated from the surface of a murine leukemia cell line. Biochim Biophys Acta. 1998, 1371: 351-362.CrossRefPubMed
42.
Scherer JM, Stillwell W, Jenski LJ: Spleen cell survival and proliferation are differentially altered by docosahexaenoic acid. Cell Immunol. 1997, 180: 153-161. 10.1006/cimm.1997.1187.CrossRefPubMed
43.
Zerouga M, Stillwell W, Stone J, Powner A, Jenski LJ: Phospholipid class as a determinant in docosahexaenoic acid's effect on tumor cell viability. Anticancer Res. 1996, 16: 2863-2868.PubMed
44.
Dratz EA, Deese AJ: The role of docosahexaenoic acid (22:6ω3) in biological membranes: examples from photoreceptors and model membrane bilayers. Health Effects of Polyunsaturated Fatty Acids in Seafoods. Edited by: Simopoulos AP, Kifer RR, Martin RE. 1986, Orlando, FL: Academic Press, 319-351.CrossRef
45.
Salem NJ, Kim HY, Yergey JA: Docosahexaenoic acid: membrane function and metabolism. Health Effects of Polyunsaturated Fatty Acids in Seafoods. Edited by: Simopoulos AP, Kifer RR, Martin RE. 1986, Orlando, FL: Academic Press, 263-317.CrossRef
46.
Balasubramanian SV, Campbell RB, Straubinger RM: Propofol, a general anesthetic, promotes the formation of fluid phase domains in model membranes. Chem Phys Lipids. 2002, 114: 35-44. 10.1016/S0009-3084(01)00199-2.CrossRefPubMed
47.
Stillwell W, Wassall SR: Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids. 2003, 126: 1-27. 10.1016/S0009-3084(03)00101-4.CrossRefPubMed
48.
Siddiqui RA, Jenski LJ, Neff K, Harvey K, Kovacs R, Stillwell W: Docosahexanoic acid induces apoptosis in Jurkat cells by a protein phosphatase-mediated process. Biochim Biophys Acta. 2001, 1499: 265-275. 10.1016/S0167-4889(00)00128-2.CrossRefPubMed
49.
Siddiqui RA, Jenski LJ, Wiesehan JD, Hunter MV, Kovacs RJ, Stillwell W: Prevention of docosahexaenoic acid-induced cytotoxicity by phosphatidic acid in Jurkat leukemic cells: the role of protein phosphatase-1. Biochim Biophys Acta. 2001, 1541: 188-200. 10.1016/S0167-4889(01)00143-4.CrossRefPubMed
Metadata
Title
Anticancer properties of propofol-docosahexaenoate and propofol-eicosapentaenoate on breast cancer cells
Authors
Rafat A Siddiqui
Mustapha Zerouga
Min Wu
Alicia Castillo
Kevin Harvey
Gary P Zaloga
William Stillwell
Publication date
01-10-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1036

Other articles of this Issue 5/2005

Breast Cancer Research 5/2005 Go to the issue

Commentary

Treating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway

Research article

Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells

Research article

Strong evidence that the common variant S384F in BRCA2has no pathogenic relevance in hereditary breast cancer

Research article

Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance

Research article

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells

Research article

The expression of the ubiquitin ligase subunit Cks1 in human breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits